- Home
- IHS vs MLYS Comparison
IHS vs MLYS Comparison
Compare IHS & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IHS
- MLYS
- Stock Information
- Founded
- IHS 2001
- MLYS 2019
- Country
- IHS United Kingdom
- MLYS United States
- Employees
- IHS N/A
- MLYS N/A
- Industry
- IHS Telecommunications Equipment
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- IHS Telecommunications
- MLYS Health Care
- Exchange
- IHS Nasdaq
- MLYS Nasdaq
- Market Cap
- IHS 1.1B
- MLYS 893.0M
- IPO Year
- IHS 2021
- MLYS 2023
- Fundamental
- Price
- IHS $5.21
- MLYS $15.93
- Analyst Decision
- IHS Strong Buy
- MLYS Strong Buy
- Analyst Count
- IHS 5
- MLYS 3
- Target Price
- IHS $7.60
- MLYS $27.00
- AVG Volume (30 Days)
- IHS 810.7K
- MLYS 2.1M
- Earning Date
- IHS 03-18-2025
- MLYS 05-08-2025
- Dividend Yield
- IHS N/A
- MLYS N/A
- EPS Growth
- IHS N/A
- MLYS N/A
- EPS
- IHS N/A
- MLYS N/A
- Revenue
- IHS $1,711,225,000.00
- MLYS N/A
- Revenue This Year
- IHS N/A
- MLYS N/A
- Revenue Next Year
- IHS $7.13
- MLYS N/A
- P/E Ratio
- IHS N/A
- MLYS N/A
- Revenue Growth
- IHS N/A
- MLYS N/A
- 52 Week Low
- IHS $2.44
- MLYS $8.24
- 52 Week High
- IHS $5.75
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- IHS 74.50
- MLYS 59.01
- Support Level
- IHS $5.16
- MLYS $16.15
- Resistance Level
- IHS $5.42
- MLYS $17.21
- Average True Range (ATR)
- IHS 0.32
- MLYS 1.23
- MACD
- IHS 0.10
- MLYS -0.10
- Stochastic Oscillator
- IHS 75.67
- MLYS 46.83
About IHS IHS Holding Limited
IHS Holding Ltd is an independent owner, operator, and developer of shared telecommunications infrastructure. The company provides telecommunications infrastructure to its customers, most of who are MNOs, who in turn provide wireless voice and data services to their end-users. Its geographical segments are Nigeria, Sub-Saharan Africa, Middle East and North Africa (MENA), and Latin America (Latam). The majority of its revenue is derived from Nigeria.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.